198 related articles for article (PubMed ID: 31398461)
1. Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation.
Miyake K; Okumi M; Kakuta Y; Unagami K; Furusawa M; Ishida H; Tanabe K
Transpl Immunol; 2019 Dec; 57():101230. PubMed ID: 31398461
[TBL] [Abstract][Full Text] [Related]
2. Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation.
Contreras AG; Casillas-Abundis A; Alberú J; Llorente L; Lima G; Arvizu A; de Santiago A; Vilatobá M; Granados J; Morales-Buenrostro LE; Cruz R; Arreola-Guerra JM
Transpl Immunol; 2018 Oct; 50():8-14. PubMed ID: 29885443
[TBL] [Abstract][Full Text] [Related]
3. Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation.
Bertrand D; Kaveri R; Laurent C; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Thierry A; François A; Hau F; Etienne I; Guerrot D; Farce F
PLoS One; 2021; 16(4):e0249934. PubMed ID: 33886604
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
[No Abstract] [Full Text] [Related]
5. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
[TBL] [Abstract][Full Text] [Related]
7. Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes.
Redondo-Pachón D; Pérez-Sáez MJ; Mir M; Gimeno J; Llinás L; García C; Hernández JJ; Yélamos J; Pascual J; Crespo M
Hum Immunol; 2018 Jun; 79(6):424-431. PubMed ID: 29524568
[TBL] [Abstract][Full Text] [Related]
8. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
[TBL] [Abstract][Full Text] [Related]
9. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.
Lan JH; Gjertson D; Zheng Y; Clark S; ; Reed EF; Cecka MJ
Am J Transplant; 2018 Dec; 18(12):2934-2944. PubMed ID: 29659162
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies.
Kovandova B; Slavcev A; Sekerkova Z; Honsova E; Trunecka P
HLA; 2018 Dec; 92 Suppl 2():34-37. PubMed ID: 30054978
[TBL] [Abstract][Full Text] [Related]
12. Low-MFI (median fluorescence intensity) pre-transplant DSA (donor specific antibodies) leading to anamnestic antibody mediated rejection in live-related donor kidney transplantation.
Chauhan R; Tiwari AK; Aggarwal G; Gowri Suresh L; Kumar M; Bansal SB
Transpl Immunol; 2023 Dec; 81():101931. PubMed ID: 37730185
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
14. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
15. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
16. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.
Sicard A; Ducreux S; Rabeyrin M; Couzi L; McGregor B; Badet L; Scoazec JY; Bachelet T; Lepreux S; Visentin J; Merville P; Fremeaux-Bacchi V; Morelon E; Taupin JL; Dubois V; Thaunat O
J Am Soc Nephrol; 2015 Feb; 26(2):457-67. PubMed ID: 25125383
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
18. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation.
Salvadé I; Aubert V; Venetz JP; Golshayan D; Saouli AC; Matter M; Rotman S; Pantaleo G; Pascual M
Hum Immunol; 2016 Jun; 77(6):483-9. PubMed ID: 27085791
[TBL] [Abstract][Full Text] [Related]
19. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
20. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
